Biological Information
Background Information:
Dopamine receptors belong to the superfamily of G protein-coupled seven transmembrane proteins. G-protein-coupled receptors constitute one of the major signal transduction systems in eukaryotic cells. Coding sequences for these receptors, in those regions believed to contribute to the agonist-antagonist binding site, are strongly conserved across mammalian species. Various members of the dopamine receptor family are generally classified as either ‘D1-like’ or ‘D2-like’. D2-like receptors comprise the D2, D3 and D4 receptors, which inhibit activation of adenylate cyclases via coupling to G1/G0 protein.
No. of Assays on Panel:
2
Assays on Panel:
Family
GPCR
Name
D4.2 Human Dopamine GPCR GTPgammaS Agonist LeadHunter Assay - TW
Item
310500-0
Protein
D4
Organism
Human
Assay Sub Type
GTPgammaS
Family
GPCR
Name
D4.2 Human Dopamine GPCR GTPgammaS Antagonist LeadHunter Assay - TW
Item
310500-1
Protein
D4
Organism
Human
Assay Sub Type
GTPgammaS
Family:
GPCR
Sub Family:
Dopamine
Class:
Class A
Protein Name:
D4
Uniprot Number:
P21917
Gene Name:
DRD4
Gene ID:
1815
Gene Aliases:
DRD1B
Accession Number:
NM_000797
Organism:
Human
Construct Details:
Full Length, Recombinant
Cell Type:
CHO-K1
Assay Information
Assay Type:
Functional
Assay Sub Type:
GTPgammaS
Functional Mode:
Agonist & Antagonist
Detection Method:
Radiometry
Measured Response:
Scintillation
Testing Information
Procedure Summary:
Human recombinant dopamine D4.2 receptors expressed in CHO-K1 cells are used. Test compound is preincubated with 0.05 mg/ml‡ membranes and 10 µM GDP for 20 minutes at 25°C in modified HEPES buffer pH 7.4 and SPA beads are then added for another 60 minutes at 30°C. The reaction is initiated by 0.3 nM [35S]GTPgS for an additional 30 minute incubation period. Test compound-induced increase of [35S]GTPgS binding by 50 percent or more (≥50%) relative to the 300 µM dopamine response indicates possible dopamine D4.2 agonist activity. Test compound-induced inhibition of 1 µM dopamine-induced increase of [35S]GTPgS binding response by 50 percent or more (≥50%) indicates receptor antagonist activity. Note: ‡Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary.
Incubation:
30 min at 30°C
Control Inhibitor:
Spiperone
Control Activator:
Dopamine
Criteria For Significance:
≥ 50% Increase in bound [35S]GTPgammaS relative to dopamine response, ≥ 50% Inhibition of dopamine-induced bound [35S]GTPgammaS
Test Concentration / Dose:
Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM
Test Sample Requirements:
75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)
Minimum Order Quantity:
16
Turnaround Time
Standard:
20 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
CNS/Addiction/Pain
Adverse / Beneficial Action:
Dopamine D4 receptor antagonism may be useful in the treatment of psychosis, possibly without causing tardive dyskineasia and hyperprolactineamia; receptor antagonism has also been reported to reduce novelty seeking. No major pharmacological differences have been reported for the most common variants of this receptor (D4.2, D4.4 and D4.7).
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
RELATED SOLUTIONS